{"id":53276,"date":"2023-09-20T09:44:27","date_gmt":"2023-09-20T09:44:27","guid":{"rendered":"https:\/\/medsname.com\/erlonat\/"},"modified":"2026-04-30T16:30:27","modified_gmt":"2026-04-30T16:30:27","slug":"erlonat","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/erlonat\/","title":{"rendered":"Erlonat"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">Rychl\u00e1 odpov\u011b\u010f<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Erlonat<\/strong> \u2014 Erlotinib 100\/150 mg (Natco Pharma). EGFR-TKI pro nemalobun\u011b\u010dn\u00fd karcinom plic s senzibilizuj\u00edc\u00edmi mutacemi EGFR (delece exonu 19, L858R), pokro\u010dil\u00fd karcinom pankreatu (s gemcitabinem).<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/li>\n<li>Diskr\u00e9tn\u00ed balen\u00ed v oby\u010dejn\u00e9 ob\u00e1lce<\/li>\n<li>Dod\u00e1n\u00ed po cel\u00e9m sv\u011bt\u011b<\/li>\n<li>Hodnoceno v\u00edce ne\u017e 1 400 z\u00e1kazn\u00edky (<a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">\u010d\u00edst recenze<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>Z\u00e1ruka op\u011btovn\u00e9ho zasl\u00e1n\u00ed:<\/strong> pokud va\u0161e objedn\u00e1vka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f od odesl\u00e1n\u00ed, za\u0161leme ji znovu bez dal\u0161\u00edch n\u00e1klad\u016f. <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">P\u0159e\u010d\u00edst podm\u00ednky<\/a>.<\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Erlonat je expedov\u00e1n od v\u00fdrobce certifikovan\u00e9ho WHO-GMP v neutr\u00e1ln\u00edm balen\u00ed, platba prob\u00edh\u00e1 p\u0159es regulovan\u00e9ho platebn\u00edho procesora (na v\u00fdpisu z \u00fa\u010dtu bude uveden regulovan\u00fd platebn\u00ed procesor \u2014 nikdy MedsBase nebo n\u00e1zev l\u00e9ku). Ka\u017ed\u00e1 objedn\u00e1vka zahrnuje na\u0161e 20denn\u00ed poji\u0161t\u011bn\u00ed p\u0159eposl\u00e1n\u00ed.<\/p>\n<div class=\"medsbase-specialist-strip\" style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0;\"><strong>\u26a0\ufe0f Specializovan\u00e1 onkologick\u00e1 l\u00e9\u010dba pod dohledem l\u00e9ka\u0159e<\/strong> \u2014 tento l\u00e9k je zahajov\u00e1n, monitorov\u00e1n a ukon\u010dov\u00e1n onkologem nebo hematologem. D\u00e1vkov\u00e1n\u00ed z\u00e1vis\u00ed na typu n\u00e1doru, stadiu, t\u011blesn\u00e9m povrchu, funkci org\u00e1n\u016f a sou\u010dasn\u00e9 terapii. Samol\u00e9\u010dba nen\u00ed vhodn\u00e1; n\u00ed\u017ee uveden\u00e9 informace jsou vzd\u011bl\u00e1vac\u00ed a podporuj\u00ed informovan\u00e9 rozhovory s va\u0161\u00edm specialistou.<\/p>\n<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Principy t\u0159\u00eddy TKI<\/strong><br \/>Inhibitory tyrozinkin\u00e1z jsou peror\u00e1ln\u00ed c\u00edlen\u00e9 terapie. Vy\u017eaduj\u00ed specializovan\u00e9 zah\u00e1jen\u00ed, pr\u016fb\u011b\u017en\u00e9 terapeutick\u00e9 monitorov\u00e1n\u00ed hladin l\u00e9\u010diva (kde je dostupn\u00e9) a zvl\u00e1d\u00e1n\u00ed t\u0159\u00eddn\u011b specifick\u00fdch toxicit. Dodr\u017eov\u00e1n\u00ed l\u00e9\u010dby je kl\u00ed\u010dov\u00e9 \u2013 vynechan\u00e9 d\u00e1vky zvy\u0161uj\u00ed riziko selh\u00e1n\u00ed l\u00e9\u010dby. V\u011bt\u0161ina TKI jsou substr\u00e1ty CYP3A4 s v\u00fdznamn\u00fdmi l\u00e9kov\u00fdmi interakcemi.<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Akneiformn\u00ed vyr\u00e1\u017eka + interstici\u00e1ln\u00ed plicn\u00ed onemocn\u011bn\u00ed<\/strong><br \/>Klasick\u00fd \u00fa\u010dinek: akneiformn\u00ed vyr\u00e1\u017eka u 70-90% pacient\u016f \u2014 obvykle koreluje s odpov\u011bd\u00ed na l\u00e9\u010dbu. Riziko ILD &lt;1%, ale potenci\u00e1ln\u011b fat\u00e1ln\u00ed \u2014 vy\u0161et\u0159ete jakoukoli nevysv\u011btlitelnou du\u0161nost, ka\u0161el nebo hore\u010dku. U\u017e\u00edvejte nala\u010dno (potrava zdvojn\u00e1sobuje biologickou dostupnost \u2014 riziko toxicity).<\/div>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3>Co je TKI?<\/h3>\n<p>Inhibitory tyrozinkin\u00e1z blokuj\u00ed specifick\u00e9 sign\u00e1ln\u00ed dr\u00e1hy, kter\u00e9 podporuj\u00ed r\u016fst n\u00e1dorov\u00fdch bun\u011bk. Ka\u017ed\u00fd TKI je selektivn\u00ed pro r\u016fzn\u00e9 c\u00edle (EGFR pro gefitinib\/erlotinib; multikin\u00e1za pro sorafenib\/sunitinib; BCR-ABL pro nilotinib\/imatinib; BTK pro ibrutinib; JAK pro ruxolitinib; CDK4\/6 pro palbociclib).<\/p>\n<h3>Vedlej\u0161\u00ed \u00fa\u010dinky?<\/h3>\n<p>Charakteristick\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky: vyr\u00e1\u017eka (\u010dasto koreluje s odpov\u011bd\u00ed u inhibitor\u016f EGFR), pr\u016fjem, \u00fanava, ko\u017en\u00ed reakce na dlan\u00edch a plosk\u00e1ch, hypertenze (multikin\u00e1zov\u00e9 inhibitory), hepatotoxicita, prodlou\u017een\u00ed QT intervalu. Ka\u017ed\u00fd TKI m\u00e1 specifick\u00fd profil.<\/p>\n<h3>Interakce l\u00e9k\u016f?<\/h3>\n<p>V\u011bt\u0161ina TKI jsou substr\u00e1ty CYP3A4. Siln\u00e9 inhibitory (azoly, makrolidy, ritonavir, grapefruit) zvy\u0161uj\u00ed hladiny a toxicitu; siln\u00e9 induktory (rifampicin, fenytoin, karbamazepin, t\u0159ezalka te\u010dkovan\u00e1) sni\u017euj\u00ed hladiny a zvy\u0161uj\u00ed riziko selh\u00e1n\u00ed l\u00e9\u010dby.<\/p>\n<h3>U\u017e\u00edvat s j\u00eddlem?<\/h3>\n<p>N\u011bkter\u00e9 TKI (lapatinib, erlotinib) se u\u017e\u00edvaj\u00ed nala\u010dno (potrava variabiln\u011b zvy\u0161uje biologickou dostupnost). Jin\u00e9 (gefitinib, sorafenib) lze u\u017e\u00edvat s j\u00eddlem nebo bez. Konkr\u00e9tn\u00ed instrukce z\u00e1vis\u00ed na molekule \u2013 potvr\u010fte s p\u0159edepisuj\u00edc\u00edm onkologem.<\/p>\n<h3>Jak prob\u00edh\u00e1 monitorov\u00e1n\u00ed odpov\u011bdi?<\/h3>\n<p>Zobrazovac\u00ed metody (CT\/MRI\/PET) ka\u017ed\u00e9 2-3 m\u011bs\u00edce na za\u010d\u00e1tku; n\u00e1dorov\u00e9 markery, pokud jsou relevantn\u00ed. L\u00e9\u010dba pokra\u010duje, dokud je p\u0159\u00ednos; zm\u011bna p\u0159i progresi nebo nep\u0159ijateln\u00e9 toxicit\u011b.<\/p>\n<h3>Rezistence?<\/h3>\n<p>Rezistence na TKI se vyv\u00edj\u00ed v \u010dase (obvykle 9-18 m\u011bs\u00edc\u016f u solidn\u00edch n\u00e1dor\u016f). Mechanismy: mutace c\u00edle (T790M pro EGFR, T315I pro BCR-ABL), aktivace alternativn\u00edch drah, nadm\u011brn\u00e1 exprese c\u00edle. TKI nov\u00e9 generace (osimertinib, ponatinib) p\u0159ekon\u00e1vaj\u00ed specifick\u00e9 rezistentn\u00ed mutace.<\/p>\n<h3>Co kdy\u017e vynech\u00e1m d\u00e1vku?<\/h3>\n<p>Pokud si vzpomenete ve stejn\u00fd den a je to v\u00edce ne\u017e 6 hodin do dal\u0161\u00ed d\u00e1vky, u\u017eijte d\u00e1vku. Jinak vynechejte \u2013 neduplikujte d\u00e1vku. Konkr\u00e9tn\u00ed instrukce se li\u0161\u00ed podle l\u00e9ku; potvr\u010fte s onkologick\u00fdm t\u00fdmem.<\/p>\n<h3>T\u011bhotenstv\u00ed?<\/h3>\n<p>V\u0161echny TKI jsou teratogenn\u00ed \u2013 \u00fa\u010dinn\u00e1 antikoncepce b\u011bhem l\u00e9\u010dby a alespo\u0148 4-6 m\u011bs\u00edc\u016f po n\u00ed u obou partner\u016f.<\/p>\n<h3>Kardiologick\u00e9 monitorov\u00e1n\u00ed?<\/h3>\n<p>Multikin\u00e1zov\u00e9 TKI (sorafenib, sunitinib): monitorov\u00e1n\u00ed TK, EKG (QT interval), echokardiografie ve vybran\u00fdch p\u0159\u00edpadech. BCR-ABL TKI (nilotinib): povinn\u00e9 EKG na za\u010d\u00e1tku a v pr\u016fb\u011bhu \u2013 prodlou\u017een\u00ed QT intervalu.<\/p>\n<h3>N\u00e1kladov\u00e1 efektivita?<\/h3>\n<p>Generick\u00e9 inhibitory tyrozinkin\u00e1z (TKI) se v Indii a dal\u0161\u00edch jurisdikc\u00edch hojn\u011b vyr\u00e1b\u011bj\u00ed na z\u00e1klad\u011b dobrovoln\u00fdch licenc\u00ed. Ceny indick\u00fdch generik jsou v\u00fdrazn\u011b ni\u017e\u0161\u00ed ne\u017e u origin\u00e1ln\u00edch p\u0159\u00edpravk\u016f. Kvalita a bioekvivalence jsou dob\u0159e zdokumentov\u00e1ny.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed l\u00e9ky na rakovinu<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/xeloda\/\">Xeloda<\/a> \u2014 kapecitabin 500 mg \u2014 peror\u00e1ln\u00ed profarmakon 5-FU pro karcinom prsu\/kolorekta\/\u017ealudku<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/altraz\/\">Altraz<\/a> \u2014 anastrozol 1 mg \u2014 inhibitor aromat\u00e1zy pro postmenopauz\u00e1ln\u00ed karcinom prsu<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/xbira\/\">Xbira<\/a> \u2014 abirateron 250 mg \u2014 inhibitor CYP17 pro metastatick\u00fd karcinom prostaty<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/zoldria\/\">Zoldria<\/a> \u2014 kyselina zoledronov\u00e1 IV \u2014 pro kostn\u00ed metast\u00e1zy a hyperkalc\u00e9mii<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/actorise\/\">Actorise<\/a> \u2014 darbepoetin alfa \u2014 pro an\u00e9mii vyvolanou chemoterapi\u00ed<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>Zdravotn\u00ed upozorn\u011bn\u00ed:<\/strong> L\u00e9\u010dba rakoviny je vysoce individualizovan\u00e1. Konkr\u00e9tn\u00ed l\u00e9k, d\u00e1vkov\u00e1n\u00ed, re\u017eim, monitorov\u00e1n\u00ed a podp\u016frn\u00e1 p\u00e9\u010de mus\u00ed b\u00fdt stanoveny kvalifikovan\u00fdm onkologem nebo hematologem na z\u00e1klad\u011b biologie n\u00e1doru, stadia onemocn\u011bn\u00ed, p\u0159idru\u017een\u00fdch chorob a c\u00edl\u016f l\u00e9\u010dby. Tyto informace jsou vzd\u011bl\u00e1vac\u00edho charakteru; nenahrazuj\u00ed odborn\u00e9 l\u00e9ka\u0159sk\u00e9 poradenstv\u00ed.<\/div>","protected":false},"excerpt":{"rendered":"<p>Erlonat (Erlotinib 100\/150 mg) \u2014 Natco EGFR-TKI pro nemalobun\u011b\u010dn\u00fd karcinom plic se senzibilizuj\u00edc\u00edmi mutacemi EGFR a pokro\u010dil\u00fd karcinom pankreatu v kombinaci s gemcitabinem.<\/p>","protected":false},"featured_media":53277,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53276","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/53276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=53276"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/53277"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=53276"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=53276"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=53276"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=53276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}